- Conditions
- Bladder Cancer
- Interventions
- gemcitabine hydrochloride
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 98
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Leesburg, Florida + 56 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 1,852
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Urinary Incontinence
- Interventions
- solifenacin succinate, tamsulosin, placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 45 Years and older · Male only
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 67 more
- Conditions
- Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
- Interventions
- Vofatamab, Docetaxel, Placebo
- Drug
- Lead sponsor
- Rainier Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 11
- States / cities
- Gilbert, Arizona • Goodyear, Arizona • Duarte, California + 8 more
- Conditions
- HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
- Interventions
- ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Newport Beach, California • Tampa, Florida + 8 more
- Conditions
- Interstitial Cystitis, Bladder Pain Syndrome, Microbial Colonization
- Interventions
- Heparin & Alkalinized Lidocaine Bladder Instillation
- Drug
- Lead sponsor
- Walter Reed National Military Medical Center
- Federal
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, irinotecan hydrochloride
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Detrusor Hyperreflexia
- Interventions
- Oxybutynin transdermal system
- Drug
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • The Bronx, New York • Chapel Hill, North Carolina + 3 more
- Conditions
- Painful Bladder Syndrome, Interstitial Cystitis
- Interventions
- standard acupuncture treatment, Control Sham/Minimal Acupuncture
- Device
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 21 Years to 65 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Interstitial Cystitis, Bladder Pain Syndrome
- Interventions
- Polymerase Chain Reaction and Next-Generation DNA Sequencing
- Diagnostic Test
- Lead sponsor
- MicroGenDX
- Industry
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Diego, California • Camden, New Jersey + 1 more
- Conditions
- Bladder Cancer
- Interventions
- Enfortumab vedotin
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Urinary Retention, Neurogenic Bladder
- Interventions
- An intermittent urethral urinary catheter with a tip, tube and drainage eyelets
- Device
- Lead sponsor
- Hollister Incorporated
- Industry
- Eligibility
- 22 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Libertyville, Illinois
- Conditions
- Cystitis, Interstitial, Dysmenorrhea, Migraine Disorders, Pelvic Pain, Endometriosis, Visceral Pain, Chronic Pain
- Interventions
- cyclic microgestin 1/20, continuous microgestin 1/20
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 353 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Urologic Injuries, Urologic Diseases, Bladder Infection, Urinary Tract Infections, Mucosal Inflammation, Mucosal Infection, Bladder Injury, Catheter-Related Infections, Catheter Complications, Catheter; Infection (Indwelling Catheter), Pelvic Floor Disorders, Urinary Incontinence
- Interventions
- Cystosure Urinary Access System, Foley Catheter
- Device
- Lead sponsor
- The Pelvic Floor Institute
- Other
- Eligibility
- 21 Years to 70 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Bladder Cancer, Metastatic Bladder Cancer, Unresectable Bladder Carcinoma, Urothelial Carcinoma
- Interventions
- Geriatric-8 Survey, National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18), Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Urologic Neoplasms, Metastases, Neoplasm
- Interventions
- pemetrexed
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Palo Alto, California • Boca Raton, Florida + 17 more
- Conditions
- Bladder Pain Syndrome
- Interventions
- Pulsed radiofrequency ablation
- Procedure
- Lead sponsor
- Walter Reed National Military Medical Center
- Federal
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Urothelial Carcinoma, Bladder Cancer
- Interventions
- Pembrolizumab, Cryoablation, Avelumab
- Drug · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Interstitial Cystitis
- Interventions
- LiRIS® 400 mg
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Royal Oak, Michigan
- Conditions
- Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Interventions
- UGN-301, UGN-201, Gemcitabine
- Drug
- Lead sponsor
- UroGen Pharma Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 4 more
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Cetrelimab, TAR-200, Cisplatin, Gemcitabine, Conventional radiation therapy, Hypo-fractioned radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 28
- States / cities
- Loma Linda, California • Los Angeles, California • Santa Monica, California + 25 more
- Conditions
- Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
- Interventions
- Ruvidar® (TLD-1433) bladder infusion and PDT
- Combination Product
- Lead sponsor
- Theralase® Technologies Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Greenwood, Indiana • Syracuse, New York + 7 more
- Conditions
- Overactive Bladder, Insulin Resistance
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 257 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Interventions
- Nadofaragene Firadenovec, Gemcitabine, Docetaxel, Pembrolizumab
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
- Conditions
- Hemorrhagic Cystitis
- Interventions
- LP-10
- Drug
- Lead sponsor
- Lipella Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • San Francisco, California • Atlanta, Georgia + 6 more